<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1699">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139043</url>
  </required_header>
  <id_info>
    <org_study_id>20624</org_study_id>
    <secondary_id>NCI-2021-11292</secondary_id>
    <secondary_id>20624</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT05139043</nct_id>
  </id_info>
  <brief_title>Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors</brief_title>
  <official_title>Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients With Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies whether low dose dexamethasone works as well as standard dose&#xD;
      dexamethasone to reduce brain swelling after brain surgery in patients with primary brain&#xD;
      tumors or cancer that has spread from other places in the body to the brain (metastatic).&#xD;
      Surgery is an important part of the treatment of brain tumors; however, it results in injury&#xD;
      to surrounding brain tissue, leading to brain swelling. Dexamethasone is effective for&#xD;
      controlling the swelling of the brain; however, dexamethasone can cause many unwanted side&#xD;
      effects. To minimize the side effects of dexamethasone, the lowest dose needed to control&#xD;
      swelling of the brain should be used. This research study is assessing the safety of using a&#xD;
      lower than standard dose of dexamethasone after the surgery to control brain swelling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the feasibility of administering lower doses of dexamethasone post-operatively in&#xD;
      patients who have mild to moderate cerebral edema pre-operatively.&#xD;
&#xD;
      II. Describe the toxicity profile associated with post-operative lower doses and standard&#xD;
      doses of dexamethasone, separately.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Descriptively assess the consistency between the quantitative data produced by&#xD;
      strategically acquired gradient echo (STAGE) and qualitative assessments of changes in&#xD;
      cerebral edema on serial fluid-attenuated inversion recovery (FLAIR) images.&#xD;
&#xD;
      II. Quantitatively assess changes in the volume of cerebral edema post-operatively in&#xD;
      participants on Arm 1 (standard dose) and Arm 2 (low dose).&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. Describe changes in the volume of cerebral edema between pre-operative and post-operative&#xD;
      day 1 brain magnetic resonance imaging (MRIs) in Arm 1 (standard dose) and Arm 2 (low dose)&#xD;
      participants, separately.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive standard dose dexamethasone orally (PO) every 12 hours (q 12 h) for 3&#xD;
      days. On the day of surgery, patients receive standard dose dexamethasone intravenously (IV)&#xD;
      before and after the surgery. Patients receive standard dose dexamethasone IV q 12 h on days&#xD;
      1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease&#xD;
      progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.&#xD;
&#xD;
      ARM II: Patients receive lower dose dexamethasone PO q 12 h for 3 days. On the day of&#xD;
      surgery, patients receive lower dose dexamethasone IV before and after the surgery. Patients&#xD;
      receive lower dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone&#xD;
      PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity.&#xD;
      Additional doses of dexamethasone are given if needed.&#xD;
&#xD;
      After completion of surgery, patients are followed up after 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lack of feasibility</measure>
    <time_frame>Up to post-operative day 8</time_frame>
    <description>Defined as a participant requiring more than 18 mg of dexamethasone beyond the planned dose per treatment arm during the 9 day period from surgery through post-operative day 8. Feasibility will be monitored sequentially (after each patient completes study treatment), by arm. The feasibility review boundary is based on a Wald sequential probability ratio test. Rates and associated 90% Clopper and Pearson binomial confidence limits will be estimated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>All grade toxicities attributed to dexamethasone at the possible or above level. All toxicities and side effects will be summarized in tables by organ, severity, and attribution. Rates and associated 90% Clopper and Pearson binomial confidence limits will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of cerebral edema for each post-surgery brain magnetic resonance imaging (MRI)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Measured by strategically acquired gradient echo (STAGE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative assessments of cerebral edema on serial fluid-attenuated inversion recovery (FLAIR) images for each post-surgery brain MRI</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Descriptive statistics will be provided for cerebral edema volume as measure by STAGE for each arm by strata and time point.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Volume of cerebral edema for pre-operative and post-operative day 1 brain MRIs as measured by STAGE</measure>
    <time_frame>At pre-operative and post-operative day 1</time_frame>
    <description>Descriptive statistics will be provided for cerebral edema volume as measure by STAGE for each arm by strata and time point.</description>
  </other_outcome>
  <other_outcome>
    <measure>Qualitative assessments of cerebral edema on serial FLAIR images for pre-operative and post-operative day 1 brain MRIs</measure>
    <time_frame>At pre-operative and post-operative day 1</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Malignant Brain Neoplasm</condition>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Recurrent Malignant Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (standard dose dexamethasone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive standard dose dexamethasone IV before and after the surgery. Patients receive standard dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (lower dose dexamethasone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lower dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive lower dose dexamethasone IV before and after the surgery. Patients receive lower dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Arm I (standard dose dexamethasone)</arm_group_label>
    <arm_group_label>Arm II (lower dose dexamethasone)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Dxevo</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hemady</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is 18 years or older.&#xD;
&#xD;
          -  Participant has a Karnofsky Performance Status of &gt;= 60%.&#xD;
&#xD;
          -  Participant has a primary or metastatic brain tumor(s).&#xD;
&#xD;
          -  Participant can have newly diagnosed or recurrent brain tumor(s).&#xD;
&#xD;
          -  If a participant is requiring more than 3 mg orally every 12 hours (q 12 h) of&#xD;
             dexamethasone at the time of signing the consent form, it is anticipated by the&#xD;
             neurosurgeon that the participant will be able to taper down their dose of&#xD;
             dexamethasone to 3 mg orally q 12 h by 3 days before the surgery.&#xD;
&#xD;
               -  (Note: If the patient is not able to decrease their dose of dexamethasone to 3 mg&#xD;
                  orally q 12 h 3 days before surgery, the patient will not be allowed to&#xD;
                  participate in the study.)&#xD;
&#xD;
          -  Participant must have less than 10 mm of midline shift seen on pre-op brain magnetic&#xD;
             resonance imaging (MRI).&#xD;
&#xD;
          -  The neurosurgeon anticipates being able to perform a gross total resection of tumor.&#xD;
&#xD;
          -  Participant is not planning to participate in another clinical trial during the study&#xD;
             period.&#xD;
&#xD;
          -  There is no limit to the number of prior therapies for enrollment in this study.&#xD;
&#xD;
          -  All participants must have the ability to understand and the willingness to sign a&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is unable to undergo a brain MRI.&#xD;
&#xD;
          -  Participant is unable to tolerate dexamethasone.&#xD;
&#xD;
          -  Participant has a chronic or active viral infection of the central nervous system&#xD;
             (CNS).&#xD;
&#xD;
          -  Participant has a coagulopathy or bleeding disorder.&#xD;
&#xD;
          -  Participant has an uncontrolled illness including ongoing or active infection.&#xD;
&#xD;
          -  Participant has another active malignancy.&#xD;
&#xD;
          -  A patient has a serious medical or psychiatric illness that could, in the&#xD;
             investigator's opinion, potentially interfere with the safety monitoring requirements&#xD;
             and completion of treatment according to this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jana L Portnow</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jana L. Portnow</last_name>
      <phone>626-218-9200</phone>
      <email>jportnow@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jana L. Portnow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

